Literature DB >> 8444281

Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors.

M L Zeise1, S Kasparov, M Capogna, W Zieglgänsberger.   

Abstract

Acamprosate (calciumacetylhomotaurinate) is used therapeutically against relapse in weaned alcoholics. In the present study, the mechanism of action was investigated by making intracellular in vitro and extracellular in vivo recordings from rat neocortical neurons. Acamprosate (0.1-1 mM) added to the perfusion fluid in vitro reduced excitatory and inhibitory postsynaptic potentials and the depolarizing responses evoked by iontophoretic application of the excitatory amino acids, L-glutamate, L-aspartate, L-homocysteate and N-methyl-D-aspartate, but did not alter the responses to gamma-aminobutyric acid. Acamprosate decreased electrical excitability without apparently changing membrane potential, input resistance, afterhyperpolarization, or threshold and amplitude of the action potential. In vivo iontophoretic application of acamprosate reduced the extracellularly recorded unit activity elicited by iontophoretically applied L-glutamate, whereas spontaneous discharges remained unaffected. These data suggest that acamprosate reduces the postsynaptic efficacy of excitatory amino acid neurotransmitters and lowers neuronal excitability in the neocortex of the rat.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444281     DOI: 10.1016/0014-2999(93)90682-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

Review 1.  Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.

Authors:  Philippe De Witte; John Littleton; Philippe Parot; George Koob
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

Authors:  M I Wilde; A J Wagstaff
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

Review 4.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 5.  Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.

Authors:  Barbara J Mason; Charles J Heyser
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

6.  Calcium chloride mimics the effects of acamprosate on cognitive deficits in chronic alcohol-exposed mice.

Authors:  Grishma Pradhan; Patrick R Melugin; Fei Wu; Hannah M Fang; Rachel Weber; Sven Kroener
Journal:  Psychopharmacology (Berl)       Date:  2018-04-20       Impact factor: 4.530

7.  Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.

Authors:  M Scott Bowers; Billy T Chen; Jonathan K Chou; Megan P H Osborne; Justin T Gass; Ronald E See; Antonello Bonci; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2007-09-02       Impact factor: 4.530

Review 8.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 9.  Advances in alcoholic liver disease: An update on alcoholic hepatitis.

Authors:  Randy Liang; Andy Liu; Ryan B Perumpail; Robert J Wong; Aijaz Ahmed
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice.

Authors:  Ben Lewis; Dennis J Morrell; Justin M Farook; Ali Krazem; John M Littleton; Susan Barron
Journal:  Physiol Behav       Date:  2008-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.